Olmesartanmedoxomil/Amlodipin Accord (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil/amlodipine is a combination antihypertensive that acts on the renin‑angiotensin system and calcium‑channel pathways to lower blood pressure.

• Hypertension: helps achieve target blood pressure in adults.
• Hypertensive heart disease: reduces cardiac workload.
• Chronic kidney disease with hypertension: slows progression of renal impairment.
• High‑risk cardiovascular patients: lowers risk of stroke and myocardial infarction.
• Elderly patients with isolated systolic hypertension: improves systolic control.

• Olmesartan medoxil blocks the angiotensin II type 1 (AT1) receptor, preventing vasoconstriction and aldosterone release, while amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation. The combined effect reduces systemic vascular resistance and cardiac afterload, leading to sustained blood‑pressure reduction.

Common Side Effects

• Headache
• Peripheral edema
• Dizziness
• Flushing
• Fatigue
• Nasal congestion

Serious or Rare Side Effects

• Angio‑edema
• Severe hypotension
• Elevated liver enzymes
• Acute kidney injury
• Myocardial infarction in susceptible patients
• Severe allergic reactions (anaphylaxis)

Patients should be monitored for blood‑pressure response and renal function during therapy.

• Adjust dose in renal impairment: reduce if eGFR <30 mL/min/1.73 m².
• Avoid in pregnancy: contraindicated due to fetal toxicity.
• Monitor electrolytes: watch for hyperkalemia.
• Caution with concurrent diuretics: may increase hypotension risk.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Major Interactions (Avoid)

• Concomitant use with aliskiren in diabetic patients: risk of renal impairment and hyperkalemia.
• Dual ACE inhibitor/ARB therapy: increased risk of hypotension, hyperkalemia, and renal dysfunction.\nModerate Interactions (Monitor Closely):
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• Potassium‑sparing diuretics: increase risk of hyperkalemia.
• Simvastatin high dose: amlodipine can increase serum levels, raising myopathy risk.
• CYP3A4 inhibitors (e.g., itraconazole): may raise amlodipine concentrations.
• CYP3A4 inducers (e.g., rifampicin): may reduce amlodipine efficacy.